Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pharmaceuticals
Chinese Biotech Raises $97 Million
by Jean-François Tremblay
May 25, 2015
| A version of this story appeared in
Volume 93, Issue 21
The oncology research firm BeiGene has raised $97 million from private equity investors to sustain existing drug research programs. The company has three cancer drug candidates undergoing Phase I clinical trials and several other programs at the preclinical stage. Based in Beijing and employing 170 people, BeiGene is headed by the U.S. entrepreneur John V. Oyler, who previously launched the drug discovery services firm BioDuro in China.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter